Our Mission

Our central mission is to improve the lives of patients who are suffering from cancer by conducting cutting-edge basic and clinical research and providing the highest quality patient care.
We strive to have a lasting and meaningful impact on the life of every patient that we treat.

Since its inception, the Stanford Center for Cancer Cell Therapy (CCT) has driven new scientific discoveries, improved the safety and efficacy of CAR-T cell therapies, and conducted cutting-edge translational research.

Working closely with the Stanford Cancer Institute to recruit new faculty members and engage existing ones in this new area of research, CCT has amassed an impressive team of scholars who are collectively engaged in advancing the field and the work of the Center.

Our model for bench-to-bedside-to-bench research is an exemplar for efforts throughout Stanford Medicine to apply fundamental discoveries to advance human health.

Member Highlights

In 2020, we launched our first investigator-initiated trial targeting solid tumors and have seen promising clinical results.

This study builds upon collaborative work undertaken with Michelle Monje, MD, PhD wherein we demonstrated activity of GD2-CAR T cells for a lethal pediatric brain tumor—diffuse intrinsic pontine glioma.

We are very proud of the short time period between identifying the effectiveness of this CAR in mouse models and then delivering a novel therapeutic to the clinic, which is only possible due to the creation of a sustained infrastructure for bench-to-bedside translation.